Next generation antidepressants with novel mechanisms for treatment resistant depression.
Mu-Hong Chen, Pei-Chi Tu, Tung-Ping Su
Progress in brain research January 1, 2023 DOI: 10.1016/bs.pbr.2023.02.005 via PubMed
Summary
AI-generated from the abstractPsychedelic drugs such as ketamine and psilocybin rapidly alter consciousness and neuroplasticity by modulating N-methyl-d-aspartate receptors and 5-hydroxytryptamine receptors. The US Food and Drug Administration approved esketamine for treatment-resistant depression in 2019 and for major depressive disorder with suicidal ideation in 2020. Phase 2 clinical trials have also found rapid and sustained antidepressant effects of psilocybin in patients with treatment-resistant depression. This chapter discusses the complex relationships among consciousness, neuroplasticity, and novel rapid-acting antidepressants, along with their possible neurological mechanisms.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Depression Ketamine Neuroplasticity Psilocybin |
| Keywords | Consciousness Novel antidepressants |
| Citations | 3 |
| Key finding | Psychedelic drugs like ketamine and psilocybin modulate NMDARs and 5-HTRs to rapidly alter consciousness and neuroplasticity, and have shown rapid and sustained antidepressant effects in treatment-resistant depression. |
Abstract
Evidence has suggested that the modulation of N-methyl-d-aspartate receptors (NMDARs) and 5-hydroxytryptamine receptors (5-HTRs) via the psychedelic drugs, such as ketamine and psilocybin, rapidly alters the state of consciousness and the neuroplasticity. The United State Food and Drug Administration approved the indications of esketamine for treatment-resistant depression (TRD) in 2019 and major depressive disorder with suicidal ideation in 2020. The phase 2 clinical trials also discovered the rapid and sustained antidepressant effects of psilocybin among patients with TRD. In this chapter, we discussed the complex among the consciousness, neuroplasticity, and novel rapid-acting antidepressants and their possible neuromechanisms.